Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06023199 · ClinicalTrials.gov registry record · Phase 2
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
A Phase 2 study of Sickle Cell Disease, sponsored by Inova Health Care Services.
- Active
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06023199 is a Phase 2 study of Sickle Cell Disease that is active but no longer recruiting, run by Inova Health Care Services. The registered enrollment target is 6 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06023199, a Phase 2 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by Inova Health Care Services.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effects of treatment on physical function in patients with SCD. The hypothesis to be tested is that anemic SCD patients will have improvements in performance after 6 months of voxelotor treatment.
Conditions Studied
Interventions
- DRUG Voxelotor
Study Locations (1)
Virginia
- Inova Schar Cancer Institute - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06023199
The ClinicalTrials.gov registry entry for NCT06023199 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower). The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Voxelotor is the first listed.
NCT06023199 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06023199 about?
NCT06023199 is a clinical study titled "Assessing Physical Function in Sickle Cell Patients Taking Voxelotor". Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effect...
What is the current status of trial NCT06023199?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2023-10-23. Estimated completion is 2026-06-15.
What conditions does trial NCT06023199 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT06023199?
The interventions under investigation include: Voxelotor (DRUG).
Who is sponsoring clinical trial NCT06023199?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06023199 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.